{{Rsnum
|rsid=2922126
|Gene=GHSR
|Chromosome=3
|position=172449471
|Orientation=plus
|GMAF=0.3007
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;T)
|geno3=(T;T)
|Gene_s=GHSR
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;T)
| geno3=(T;T)
| CEU | 7.7 | 40.0 | 52.3
| HCB | 13.6 | 59.1 | 27.3
| JPT | 20.5 | 50.0 | 29.5
| YRI | 0.0 | 9.5 | 90.5
| ASW | 0.0 | 0.0 | 0.0
| CHB | 13.6 | 59.1 | 27.3
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2922126
|Name_s=
|Gene_s=GHSR
|Feature=
|Evidence=PubMed ID:19024096
|Annotation=A study of 698 patients, diagnosed as metabolic syndrome, and 762 controls found that the rs2922126 SNP in the promoter of GHSR was associated with metabolic syndrome, increased waist circumference, and increased fast blood glucose in Chinese women.
|Drugs=
|Drug Classes=
|Diseases=metabolic syndrome
|Curation Level=Curated
|PharmGKB Accession ID=PA162411188
}}

{{PMID Auto
|PMID=20404923
|Title=Family and population-based studies of variation within the ghrelin receptor locus in relation to measures of obesity.
|OA=1
}}

{{PMID Auto
|PMID=21269581
|Title=Analysis of the influence of the ghrelin receptor rs509035, rs512692 and rs2922126 polymorphisms in the risk of cardiovascular disease in patients with rheumatoid arthritis.
}}

{{PMID Auto
|PMID=22457237
|Title=GH secretagogue receptor gene polymorphisms are associated with stature throughout childhood.
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2922126
|overall_frequency_n=37
|overall_frequency_d=128
|overall_frequency=0.289062
|n_genomes=20
|n_genomes_annotated=0
|n_haplomes=26
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=24340245
|Title=Adiposity, inflammation, genetic variants and risk of post-menopausal breast cancer findings from a prospective-specimen-collection, retrospective-blinded-evaluation (PRoBE) design approach
|OA=1
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}